SHARPIN and metabolic dysfunction-associated steatohepatitis: These results indicate that SHARPIN suppression in the liver can trigger inflammation, fibrosis, and apoptosis, all of which are characteristic features not only distinguishing NASH from simple steatosis [16], but also observed in acute liver injury models produced by administration of CCl4 or APAP (Figure 1c,f).